Many scientific studies have shown the health impacts of air pollution.
Teams from the Georges-Pompidou European Hospital AP-HP, the University of Paris, Inserm and the Presbyterian Hospital in New York carried out work to demonstrate the blood pressure benefit of endovascular renal denervation by focused ultrasound.
In a new study, researchers show that a significant proportion of patients who were hospitalized and followed up as part of French COVID continue to have symptoms three and six months after infection.
Loss of smell, or anosmia, is one of the earliest and most commonly reported symptoms of COVID-19.
Grâce à une importante analyse génomique des cancers du foie de l'enfant, l'équipe du Professeure Jessica Zucman-Rossi au Centre de Recherche des Cordeliers (Université de Paris, Inserm, Sorbonne Université), et ses collaborateurs du réseau Hepatobio, ont identifié de nouveaux mécanismes de résistance à la chimiothérapie.
Researchers from the ComPaRe cohort (Community of Patients for Research, compare.aphp.fr ), led by Prof. Philippe Ravaud, AP-HP / University of Paris / Inserm, used an original method to develop and validate the first measurement science of the severity of the disease and its impact on the lives of patients.
A long-acting antibody (LAAB) combination developed by AstraZeneca is to be evaluated in DisCoVeRy, the Inserm-coordinated European trial aimed at finding a treatment for COVID-19.
A l’âge de 5 ans et demi, 35% des enfants nés extrêmes prématurés, près de 45% des grands prématurés et 55% de ceux nés modérément prématurés auront une trajectoire développementale proche de la normale.
Teams from AP-HP, Sorbonne University and Inserm at the Pierre Louis Institute of Epidemiology and Public Health, coordinated by Dr Youri Yordanov and Prof. Agnès Dechartres, assessed the clinical characteristics, fate and factors associated with hospitalization or death of ambulatory patients followed using the COVIDOM device.
The severe form of Covid-19 is known to be associated with the excessive elevation of many cytokines, a condition termed “cytokine storm”. Therapy with biological agents intended to block these cytokines, for example anti-interleukin-6 or anti-interleukin-1 antibodies, was already tried, albeit with a limited success. A recent study shows that there are at least two distinct types of cytokine storms induced by SARS-CoV-2 infection that are differentially associated with...